This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Mechanism of action == Methylnaltrexone is a peripheral acting mu-opioid receptor antagonist, and does not cross the blood brain barrier. Methylnaltrexone has restricted access through the blood brain barrier because it is a quaternary amine, which carries a positive charge when in a solution. This positive charge increases polarity and decreases lipid solubility when compared to traditional opioid agonists used for pain treatment. The peripheral action of methylnaltrexone makes it effective for decreasing the constipating effects of opioids, without interfering with the analgesic effects (of opioids) on the central nervous system. This is the primary characteristic that makes methylnaltrexone behave differently than naltrexone. Furthermore, as methylnaltrexone cannot cross the blood–brain barrier, it does not reverse the pain-killing properties of opioid agonists or cause withdrawal symptoms, but since a small portion of analgesia comes from the peripheral opioid receptors, it can increase pain from inflammatory conditions such as arthritis.
== Characteristics of drugs candidate to therapeutic drug monitoring == In pharmacotherapy, many medications are used without monitoring of blood levels, as their dosage can generally be varied according to the clinical response that a patient gets to that substance. For certain drugs, this is impracticable, while insufficient levels will lead to undertreatment or resistance, and excessive levels can lead to toxicity and tissue damage. Indications in favor of therapeutic drug monitoring include:
=== DPP-4 inhibitor trials === McGuire served on the executive committees of four cardiovascular outcome trials (CVOTs) evaluating DPP-4 inhibitors: SAVOR-TIMI 53 (saxagliptin), TECOS (sitagliptin), CAROLINA (linagliptin), and CARMELINA (linagliptin). He was co-chair of CARMELINA. These trials were designed to establish non-inferiority for major adverse cardiovascular events (MACE). SAVOR-TIMI 53 reported an increased risk of hospitalization for heart failure with saxagliptin.
== Biological role and toxicity == Dichloroacetylene causes severe neurological disorders, among other problems. Main route of human exposure to dichloroacetylene has been the breakdown of trichloroethylene in presence of alkali hydroxides, historically during trichloroethylene anaesthesia when soda lime was used. Humans exposed to dichloroacetylene showed symptoms such as nausea, vomiting, loss of appetite, headache, facial nervous and muscular issues, and formation of herpes-like lesions on the face. Some people reported itching around the eyes and pain around the jaw. It affects the trigeminal nerve in particular and over-exposure could be fatal. Studies on male rats and rabbits have shown that inhalation of dichloroacetylene can cause tubular necrosis, focal necrosis, and other nephrotoxic effects. Additionally, the rabbits that were given dichloroacetylene experienced hepatotoxic and neuropathological effects. Inhalation of dichloroacetylene also causes benign tumors of the livers and kidneys of rats. The chemical also caused increased instances of lymphomas. It also causes weight loss in animals. 3.5% of a dose of dichloroacetylene remains in the corpses of male Wistar rats. The LC50s of mice exposed to dichloroacetylene are 124 parts per million for a 1-hour exposure by inhalation and 19 parts per million for a 6-hour exposure by inhalation. The chemical is ingested primarily through glutathione-dependent systems. Glutathione also reacts with it. Hepatic and renal glutathione S-transferases serve as catalysts to this reaction.
Sources: en.wikipedia.org
==== Fragmentation tree computation ==== A fragmentation tree is a representation of the fragmentation process similar to "fragmentation diagrams" created by experts. The fragmentation tree annotates the MS2 spectrum by providing a molecular formula for each fragment peak. Peaks that do not receive an annotation are considered noise peaks. The fragmentation tree also predicts the fragmentation reactions (called losses) leading to the fragment peaks. Fragmentation trees are a valuable tool for deducing information about the fragmentation but are not a precise depiction of the actual fragmentation process. To identify the molecular formula of an unknown molecule, a separate fragmentation tree is computed for every molecular formula candidate. In other words, the method attempts to reconstruct the fragmentation process that led to this MS2 spectrum for each candidate molecular formula. This allows to compare the different hypotheses that a particular candidate is actual the correct molecular formula. The best-scoring fragmentation tree (i.e. the fragmentation process that is best explaining the spectrum) corresponds to the most likely molecular formula explanation.
==== Kazakhstan ==== Institute of World Economics and Politics (IWEP) at the Foundation of the First President of the Republic of Kazakhstan was created in 2003. IWEP activities aimed at research problems of the world economy, international relations, geopolitics, security, integration and Eurasia, as well as the study of the First President of the Republic of Kazakhstan and its contribution to the establishment and strengthening of Kazakhstan as an independent state, the development of international cooperation and the promotion of peace and stability. The Kazakhstan Institute for Strategic Studies under the President of the RK (KazISS) was established by the Decree of the President of RK on 16 June 1993. Since its foundation the main mission of the Kazakhstan Institute for Strategic Studies under the President of the Republic of Kazakhstan, as a national think tank, is to maintain analytical and research support for the President of Kazakhstan.
==== Income distribution ==== The duration and expansion of the national conflict has had a significant impact on the distribution of income and wealth in Colombia. According to an investigation by the CEDE of the University of the Andes (Universidad de los Andes), "as a result of the displacement, the displaced households have left behind a little more than four million hectares, which correspond to 6.7 times of the total hectares granted by the program of Agrarian Reform during the period between 1993 and 2000, and represent a total value of $ 2.6 billion." In this context, the enormous concentration of rural property in the hands of a few individuals is not only the result of the purchase of land by drug traffickers and the illegal appropriation by groups outside the law, but also the consequence of acquisition of properties devalued due to the armed conflict. It is estimated that 1.3% of the owners control 48% of the best lands. A study carried out by the United Nations Development Program (UNDP) states that the Colombian conflict has had a negative effect on the income of the population. According to this study, because of the conflict, Colombia has lost 17% of its per capita income in the last ten years. That is to say, "[...] the money wasted every year corresponds to about 4.6 times what the community welfare homes programs, children's homes and school restaurants of the social support network cos."
Sources: en.wikipedia.org
The mechanism of the Hofmeister series is not entirely clear, but seems to result mainly from effects on the solvent at higher salt concentrations (> 100 mM). Early members of the series increase solvent surface tension and decrease the solubility of nonpolar molecules (salt out); in effect, they strengthen the hydrophobic interaction. By contrast, later salts in the series increase the solubility of nonpolar molecules (salt in) and decrease the order in water; in effect, they weaken the hydrophobic effect. However, these salts also interact directly with proteins (which are charged and have strong dipole moments) and may even bind specifically (e.g., phosphate and sulfate binding to ribonuclease A). Ions that have a strong salting in effect such as I− and SCN− are strong denaturants, because they salt in the peptide group, and thus interact much more strongly with the unfolded form of a protein than with its native form. Consequently, they pull the unfolding reaction. Moreover, they may have direct interactions with some standard hydrophobic molecules, e.g., benzene. A quantum chemical investigation suggests an electrostatic origin of the Hofmeister series, which appears to quantify this qualitative series (at least for anions).
pH (rate increases with increasing pH ( 6–8.5)), presence of halide ions (cause Ag+ precipitation), particle coating presence of reducing sugars. The presence of cysteine (inhibits dissolution). presence of natural organic matter.
The 17-bp transcriptional complex has an 8-bp DNA-RNA hybrid, that is, 8 base-pairs involve the RNA transcript bound to the DNA template strand. As transcription progresses, ribonucleotides are added to the 3′ end of the RNA transcript and the RNAP complex moves along the DNA. The characteristic elongation rates in prokaryotes and eukaryotes are about 10–100 nts/sec. Aspartyl (asp) residues in the RNAP will hold on to Mg2+ ions, which will, in turn, coordinate the phosphates of the ribonucleotides. The first Mg2+ will hold on to the α-phosphate of the NTP to be added. This allows the nucleophilic attack of the 3′-OH from the RNA transcript, adding another NTP to the chain. The second Mg2+ will hold on to the pyrophosphate of the NTP. The overall reaction equation is:
== Diagnosis == Because of the varying symptoms of aortic dissection, the diagnosis is sometimes difficult to make. Concern should be increased in those with low blood pressure, neurological problems, and unequal pulses. The diagnosis of aortic dissection is made by visualization of the intimal flap on a diagnostic imaging test. The gold standard test is CT angiography of the aorta. Other possible tests include a CT scan of the chest, cardiac magnetic resonance (MRI), or echocardiography.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.